Kodiak Sciences Inc. (KOD) stock
KODNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$96.80−3.93 (-3.90%)
Close on Nov 17, 2026Market cap $6.08BP/E –Yield –
Kodiak Sciences cash
Cash and short-term investments held at the end of each period.
Kodiak Sciences's cash was $125.90M at Jun 30, 2026. For fiscal 2025 it was $209.86M, up 24.9% from the year before. The highest annual figure on record is $968.97M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.86M | +24.9% |
| FY2024 | Dec 31, 2024 | $168.07M | -41.1% |
| FY2023 | Dec 31, 2023 | $285.51M | -40.4% |
| FY2022 | Dec 31, 2022 | $478.93M | -34.5% |
| FY2021 | Dec 31, 2021 | $731.51M | -24.5% |
| FY2020 | Dec 31, 2020 | $968.97M | +188.0% |
| FY2019 | Dec 31, 2019 | $336.48M | +281.3% |
| FY2018 | Dec 31, 2018 | $88.25M | +6226.5% |
| FY2017 | Dec 31, 2017 | $1.40M | -85.5% |
| FY2016 | Dec 31, 2016 | $9.62M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $125.90M | +20.9% |
| Q1 FY2026 | Mar 31, 2026 | $169.53M | +22.1% |
| Q4 FY2025 | Dec 31, 2025 | $209.86M | +24.9% |
| Q3 FY2025 | Sep 30, 2025 | $72.04M | -63.6% |
| Q2 FY2025 | Jun 30, 2025 | $104.17M | -52.5% |
| Q1 FY2025 | Mar 31, 2025 | $138.85M | -43.5% |
| Q4 FY2024 | Dec 31, 2024 | $168.07M | -41.1% |
| Q3 FY2024 | Sep 30, 2024 | $197.86M | -42.8% |
| Q2 FY2024 | Jun 30, 2024 | $219.23M | -42.1% |
| Q1 FY2024 | Mar 31, 2024 | $245.92M | -41.6% |
| Q4 FY2023 | Dec 31, 2023 | $285.51M | -40.4% |
| Q3 FY2023 | Sep 30, 2023 | $345.67M | -35.7% |
| Q2 FY2023 | Jun 30, 2023 | $378.67M | -36.7% |
| Q1 FY2023 | Mar 31, 2023 | $421.19M | -37.3% |
| Q4 FY2022 | Dec 31, 2022 | $478.93M | -34.5% |
| Q3 FY2022 | Sep 30, 2022 | $537.40M | -32.8% |
| Q2 FY2022 | Jun 30, 2022 | $597.88M | -32.1% |
| Q1 FY2022 | Mar 31, 2022 | $671.73M | -27.7% |
| Q4 FY2021 | Dec 31, 2021 | $731.51M | -24.5% |
| Q3 FY2021 | Sep 30, 2021 | $799.20M | +110.0% |
| Q2 FY2021 | Jun 30, 2021 | $880.90M | +111.2% |
| Q1 FY2021 | Mar 31, 2021 | $929.00M | +115.8% |
| Q4 FY2020 | Dec 31, 2020 | $968.97M | +188.0% |
| Q3 FY2020 | Sep 30, 2020 | $380.50M | +527.9% |
| Q2 FY2020 | Jun 30, 2020 | $417.10M | +512.5% |
| Q1 FY2020 | Mar 31, 2020 | $430.40M | +430.9% |
| Q4 FY2019 | Dec 31, 2019 | $336.48M | +281.3% |
| Q3 FY2019 | Sep 30, 2019 | $60.60M | +422.9% |
| Q2 FY2019 | Jun 30, 2019 | $68.10M | +286.0% |
| Q1 FY2019 | Mar 31, 2019 | $81.08M | +255.4% |
| Q4 FY2018 | Dec 31, 2018 | $88.25M | +6226.5% |
| Q3 FY2018 | Sep 30, 2018 | $11.59M | +81.3% |
| Q2 FY2018 | Jun 30, 2018 | $17.64M | +83.3% |
| Q1 FY2018 | Mar 31, 2018 | $22.81M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.40M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.62M | – |
See a number that looks wrong?